Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Anemia
Antineoplastic Combined Chemotherapy Protocols
Area Under Curve
Bayes Theorem
Benzimidazoles
Bile Duct Neoplasms
Breast Neoplasms
Carboplatin
Carcinoma, Basal Cell
Carcinoma, Hepatocellular
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Carcinoma, Transitional Cell
Cholangiocarcinoma
Deoxycytidine
Female
Gallbladder Neoplasms
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Humans
Induction Chemotherapy
Kidney Neoplasms
Kidney Pelvis
Liver Neoplasms
Lung Neoplasms
Maintenance Chemotherapy
Male
Maximum Tolerated Dose
Mesothelioma
Middle Aged
Nausea
Neoplasm Metastasis
Neutropenia
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Prostatic Neoplasms
Skin Neoplasms
Thrombocytopenia
Treatment Outcome

authors with profiles

Gini Fleming